Brought to you by 
Shire acquires AnorMed's Fosrenol patents
03 Oct 2006
Executive Summary
Shire Pharmaceuticals Group PLC has acquired the patents for AnorMed's Fosrenol (lanthanum carbonate), a potential kidney drug to treat hyperphosphatemia (high levels of phosphate in the blood). The condition is associated with end-stage renal disease. Shire has filed for the candidate's US, Canadian, and European Union approval, which it expects to obtain sometime this year. Fosrenol is in Phase I in Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire acquires AnorMed's Fosrenol patents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice